Nervous system

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

Retrieved on: 
Friday, February 23, 2024
Virtual, Nervous system, AMIX, Management

THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor Lunch Break: The Autonomix Opportunity event on Thursday, February 29, 2024 at 12:00 PM ET.

Key Points: 
  • Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29th at 12:00 PM ET
    THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor Lunch Break: The Autonomix Opportunity event on Thursday, February 29, 2024 at 12:00 PM ET.
  • As part of the event, Lori Bisson, Chief Executive Officer of Autonomix, will provide a corporate overview, business outlook, and discuss the Autonomix opportunity.
  • A live video webcast of the event will be available on the Events page under the Investors section of the Company’s website ( autonomix.com ).
  • A webcast replay will be available two hours following the live event and will be accessible for 90 days.

Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study

Retrieved on: 
Thursday, February 22, 2024
Nervous system, POC, AMIX, Principal, Collateral damage, Pain, Principal investigator, Patient, Disease, Trial of the century, Ethanol, Medical imaging

THE WOODLANDS, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed selection of Principal Investigators for its proof-of-concept human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain. Additionally, the Principal Investigators have successfully completed training for the PoC study.

Key Points: 
  • Additionally, the Principal Investigators have successfully completed training for the PoC study.
  • “We are building important momentum with the advancement of our PoC human clinical study.
  • We worked diligently to identify and secure our Principal Investigators for the study and have completed the training for this first study ever to evaluate RF ablation in a transvascular approach.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the study.

apexanalytix Transforms Supplier Management with Generative AI Platform

Retrieved on: 
Thursday, March 7, 2024
Data Management, Security, Technology, Logistics, Supply Chain Management, Transport, Software, Artificial Intelligence, Friction, Artificial intelligence, AI, Nervous system, Risk management, ChatGPT, Communication, Documentation, Behavior, Organization, Automation, Child, Sales

Today, apexanalytix , the leading provider of global supply chain risk management data, software and services, announces the launch of apex Neural Engine, an AI-powered solution poised to shape the future of the supplier management landscape.

Key Points: 
  • Today, apexanalytix , the leading provider of global supply chain risk management data, software and services, announces the launch of apex Neural Engine, an AI-powered solution poised to shape the future of the supplier management landscape.
  • The rise of large language models (LLMs) like ChatGPT has deeply impacted the supplier management space, with 50% of supply chain leaders actively planning to deploy generative AI in the next twelve months.
  • While off-the-shelf AI solutions can offer convenience, they also come with a unique set of challenges and limitations.
  • With the release of apex Neural Engine, apexanalytix aims to streamline supplier interactions, improve communication, and ultimately contribute to more robust risk management strategies so organizations can navigate the complex supplier landscape with confidence.

Pioneering work in computational and theoretical neuroscience is awarded the world’s largest brain research prize

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Other Science, Medical Devices, Research, Software, Science, Nervous system, Multimedia, AI, Neuroscience, Courage, Intelligence, Brain, Neuron, Schizophrenia, Language, Harvard University, Mathematics, Learning, Perception, Physics, Computation, Foundationalism, Memory, The Brain Prize, Cognition, Epilepsy, Knowledge, Imagination, Columbia University, Hebrew University of Jerusalem, Pharmaceutical industry

The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience.

Key Points: 
  • The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience.
  • View the full release here: https://www.businesswire.com/news/home/20240305504553/en/
    Theoretical and computational neuroscience permeates neuroscience today and is of increasingly growing importance.
  • The Brain Prize 2024 worth DKK 10 million (€1.3 million) is awarded to:
    Larry Abbott (USA), Terrence Sejnowski (USA), and Haim Sompolinsky (Israel/USA) for their Foundational work in Computational and Theoretical Neuroscience.
  • Chair of The Brain Prize Selection Committee, Professor Richard Morris, explains the reasoning behind this year’s award:
    “It is inconceivable to imagine modern brain sciences without the concomitant development of computational and theoretical neuroscience.

Soul Machines to Unveil Groundbreaking Digital Marilyn Monroe at SXSW 2024

Retrieved on: 
Friday, March 8, 2024
SXSW, SAN, Authentic Brands Group, Nervous system, Emotion, AI, Individual, Digital, Emotional Intelligence, Information, Human, World Health Organization, Authenticity, Knowledge, Emotional intelligence, Machine learning, Deep learning, Biology, Partnership

SAN FRANCISCO, March 8, 2024 /PRNewswire/ -- Soul Machines, the leader in Biological AI-powered Digital People™, today unveiled "Digital Marilyn," a groundbreaking new project in partnership with Authentic Brands Group (Authentic).

Key Points: 
  • SAN FRANCISCO, March 8, 2024 /PRNewswire/ -- Soul Machines, the leader in Biological AI-powered Digital People™, today unveiled "Digital Marilyn," a groundbreaking new project in partnership with Authentic Brands Group (Authentic).
  • The company will provide an exclusive first look at Digital Marilyn at SXSW in Austin, Texas, on March 8, 2024.
  • Digital Marilyn interacts with fans in real-time using advanced natural language processing, deep learning and GPT 3.5.
  • "This collaboration exemplifies the transformative power of AI in connecting brands and consumers," said Greg Cross, CEO and Co-founder of Soul Machines.

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

Retrieved on: 
Friday, March 8, 2024
IIT, Division, Nervous system, Neurology, CD19, Stanford University, Multiple sclerosis, Safety, KYSA, Patient, Medicine, Knowledge, DSM-IV codes, Pharmaceutical industry

EMERYVILLE, Calif., March 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the signature of a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, phase 1 investigator-initiated trial (IIT) in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis. Each participant will receive a single dose of KYV-101.

Key Points: 
  • "We are grateful for the opportunity to join forces with Kyverna to explore what may prove to be paradigm-changing immunotherapy.".
  • "We are excited about the interest shown by world-class institutions like Stanford to evaluate the clinical performance of KYV-101 in patients suffering from multiple sclerosis," said Peter Maag, Ph.D., chief executive officer of Kyverna.
  • CAR T-cell therapy involves modifying a patient's T cells to recognize and remove B cells in the patient's body.
  • Kyverna plans to continue to explore additional indications for KYV-101 and develop a robust pipeline of promising product candidate immunotherapies aimed at addressing unmet medical needs in autoimmune diseases.

Does Iron Accumulate in Brain After Concussions?

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Social media, Nervous system, Alzheimer's disease, Doctor of Philosophy, Concussion, Injury, Bleeding, Defense, Stroke, Annual general meeting, DSM-IV codes, Migraine, Multiple sclerosis, Parkinson's disease, History, Mayo Clinic, Clinical professor, Headache, Epilepsy, Brain, Research, Iron, American Academy, Medical imaging

The study involved 60 people who had post-traumatic headache due to mild traumatic brain injury, or concussion.

Key Points: 
  • The study involved 60 people who had post-traumatic headache due to mild traumatic brain injury, or concussion.
  • The people with mild traumatic brain injuries were matched with 60 people who had not had concussions or post-traumatic headache.
  • All the participants had brain scans to look at iron levels in various areas of the brain, using an indirect measure for iron burden.
  • "Previous studies have shown that iron accumulation can affect how areas of the brain interact with each other," Nikolova said.

People with Essential Tremor May Have Increased Risk of Dementia

Retrieved on: 
Wednesday, March 6, 2024
Head, Master of Science, Bangladesh Technical Education Board, Social media, Nervous system, Alzheimer's disease, Arm, Physician, Thought, Stroke, Tremor, Risk, Annual general meeting, DSM-IV codes, Migraine, AAN, Prevalence, Multiple sclerosis, Parkinson's disease, Human, University, Essential tremor, Movement disorder, Dementia, Eating, Concussion, Epilepsy, Diagnosis, Brain, Research, Jaw, American Academy, Pharmaceutical industry

Essential tremor is the most common tremor disorder, more common than Parkinson's disease.

Key Points: 
  • Essential tremor is the most common tremor disorder, more common than Parkinson's disease.
  • "Not only do tremors affect a person's ability to complete daily tasks such writing and eating, our study suggests that people with essential tremor also have an increased risk of developing dementia."
  • The study involved 222 people with essential tremor who had an average age of 79 at the start of the study.
  • "While the majority of people with essential tremor will not develop dementia, our findings provide the basis for physicians to educate people with essential tremor and their families about the heightened risk, and any potential life changes likely to accompany this diagnosis," Louis said.

Allen Institute joins the Weill Neurohub

Retrieved on: 
Wednesday, March 6, 2024
Engineering, UCSF, Head, Nervous system, Helen Wills Neuroscience Institute, AI, Neurology, Stroke, DSM-IV codes, Faculty, University, Cell biology, UC, Chronic pain, Organization, Knowledge, Disease, Genomics, Science, Biology, Brain, Research, Allen Institute, University of California, Berkeley, Partnership, Pharmaceutical industry

SEATTLE, March 6, 2024 /PRNewswire/ -- The Allen Institute has officially become the newest member of the Weill Neurohub, a collaborative research network advancing treatments for neurological diseases. 

Key Points: 
  • SEATTLE, March 6, 2024 /PRNewswire/ -- The Allen Institute has officially become the newest member of the Weill Neurohub , a collaborative research network advancing treatments for neurological diseases.
  • Founded in 2003 by philanthropist Paul G. Allen, the Allen Institute focuses on big questions in biology through a team-based, open science approach, and currently has moonshot projects in neuroscience, cell biology, and immunology institutes.
  • "The expansion of the Weill Neurohub and our formal partnership with the Allen Institute represents a powerful joining of forces in neuroscience," said Stephen Hauser, M.D., the Robert A. Fishman Distinguished Professor of Neurology at UCSF and director of the UCSF Weill Institute for Neurosciences.
  • These collaborative sessions are intended to spark new joint projects and residencies, focusing on the scientific pillars of the Weill Neurohub.

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024
NMOSD, Social media, Hellwig, Nervous system, Alzheimer's disease, MD, Ofatumumab, Stroke, German, Pregnancy, Life, Risk, Annual general meeting, Multiple sclerosis, DSM-IV codes, AAN, Health, Migraine, Parkinson's disease, Hypoesthesia, Fatigue, Ruhr University Bochum, Mother, Paresthesia, Infant, Concussion, Spinal cord, Breast milk, Epilepsy, Sclerosis, Disease, Child, Rituximab, Natalizumab, Optic nerve, Brain, Demyelinating disease, Research, Immune system, American Academy, Birth control

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.